Multiple sclerosis (Houndmills, Basingstoke, England)最新文献

筛选
英文 中文
Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No. 在长期临床和放射学稳定后,稳定的老年多发性硬化症患者是否应该停止疾病改善治疗?——没有。
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1177/13524585251344805
Yi Chao Foong, Helmut Butzkueven
{"title":"Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No.","authors":"Yi Chao Foong, Helmut Butzkueven","doi":"10.1177/13524585251344805","DOIUrl":"10.1177/13524585251344805","url":null,"abstract":"","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"766-768"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study. 语音作为多发性硬化症的数字生物标志物:在横断面MS队列研究中使用多语音任务协议的语音度量的自动分析。
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-06-01 Epub Date: 2025-06-14 DOI: 10.1177/13524585251329801
Susett Garthof, Simona Schäfer, Julia Elmers, Louisa Schwed, Nicklas Linz, Tina Boggiano, Christopher Chatham, James Overell, Helen Hayward-Koennecke, Johannes Tröger, Anja Dillenseger, Björn Tackenberg, Tjalf Ziemssen
{"title":"Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.","authors":"Susett Garthof, Simona Schäfer, Julia Elmers, Louisa Schwed, Nicklas Linz, Tina Boggiano, Christopher Chatham, James Overell, Helen Hayward-Koennecke, Johannes Tröger, Anja Dillenseger, Björn Tackenberg, Tjalf Ziemssen","doi":"10.1177/13524585251329801","DOIUrl":"https://doi.org/10.1177/13524585251329801","url":null,"abstract":"<p><strong>Background: </strong>Abnormalities in speech are well-documented in people with multiple sclerosis (pwMS). Recent studies focused mainly on acoustic measures, limiting the range of speech features analyzed. The aim of this study is to include both acoustic and linguistic features and evaluate their relationship with cardinal symptoms of multiple sclerosis (MS).</p><p><strong>Methods: </strong>In a prospective study, speech of <i>N</i> = 282 native German speakers (145 healthy controls (HCs) and 137 pwMS) was recorded at the University Clinic Dresden. Participants completed an extensive speech protocol, comprising narrative, articulatory, and phonatory tasks. Speech was analyzed using the SIGMA speech features library.</p><p><strong>Results: </strong>Differences in pwMS compared with HCs were evident in instabilities in phonation and articulation (i.e. jitter: <i>H</i> = 8.17, <i>p</i> = 0.04, <i>d</i> = 0.33; standard deviation of loudness: <i>H</i> = 14.17, <i>p</i> = 0.01, <i>d</i> = 0.45) during narrative speech tasks with high cognitive load. Speech abnormalities correlated with the Expanded Disability Status Scale (i.e. jitter: <i>r</i> = 0.25, <i>p</i> < 0.01; loudness peaks: <i>r</i> = 0.26, <i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>Phonatory instabilities, changes in pitch and loudness, and reduced speech time are associated with disease severity, motor and cognitive symptoms. Speech parameters related to motor functions are influenced by cognitively demanding tasks, suggesting an interaction between functions.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":"31 7","pages":"856-865"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparison of JC virus assay performance provided with originator and biosimilar natalizumab. 原药和生物仿制药natalizumab提供的JC病毒检测性能的比较。
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-06-01 Epub Date: 2025-06-14 DOI: 10.1177/13524585251346652
James Varley, Rahma Beyrouti, Richard Nicholas, Rachel Dorsey, Wallace Brownlee, David Paling, Joela Mathews, Ruth Dobson
{"title":"A comparison of JC virus assay performance provided with originator and biosimilar natalizumab.","authors":"James Varley, Rahma Beyrouti, Richard Nicholas, Rachel Dorsey, Wallace Brownlee, David Paling, Joela Mathews, Ruth Dobson","doi":"10.1177/13524585251346652","DOIUrl":"10.1177/13524585251346652","url":null,"abstract":"<p><strong>Background: </strong>A rare complication of natalizumab treatment is progressive multifocal leukoencephalopathy (PML); risk can be stratified using JC virus (JCV) antibody status. Risk calculators to aid clinical decision-making use cohort data tested using the Stratify-JCV assay. Following concerns of an increased number of JCV seropositive results following the switch to biosimilar natalizumab and the associated test switch, we sought to understand the clinical implications.</p><p><strong>Methods: </strong>A total of 497 people with MS, who had switched from Tysabri to Tyruko with sequential results available on both assays, were included.</p><p><strong>Results: </strong>Of 250 patients negative on Stratify-JCV, 119 (47.6%) were subsequently positive on ImmunoWELL. Agreement was the poorest at lower JCV index, where positive/negative cutoffs inform risk stratification and pharmacovigilance protocols most significantly.</p><p><strong>Conclusion: </strong>These observed differences create uncertainty in how to counsel patients and best carry out PML surveillance. Specific concerns include overestimating risk leading to increased patient concern, increased monitoring burden and associated healthcare costs and lack of access to a highly effective therapy. It is incumbent on all stakeholders including pharmaceutical industry and test developers, patient groups, governmental authorities (including regulatory bodies) and clinicians to work together to find an expeditious solution.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":"31 7","pages":"882-885"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test? 除了切换到natalizumab的生物仿制药:改变JCV测试的影响是什么?
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-06-01 Epub Date: 2025-06-14 DOI: 10.1177/13524585251322683
Sandra Vukusic, Florian Hubben, Antoine Gavoille, Yannis Malek, Olivier Casez, Laurent Kremer, Thomas Palpacuer, Romain Marignier, Françoise Durand-Dubief, Géraldine Androdias-Condemine, Julie Pique, Elisabeth Maillart, Patrick Vermersch, Jérôme de Seze
{"title":"Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?","authors":"Sandra Vukusic, Florian Hubben, Antoine Gavoille, Yannis Malek, Olivier Casez, Laurent Kremer, Thomas Palpacuer, Romain Marignier, Françoise Durand-Dubief, Géraldine Androdias-Condemine, Julie Pique, Elisabeth Maillart, Patrick Vermersch, Jérôme de Seze","doi":"10.1177/13524585251322683","DOIUrl":"10.1177/13524585251322683","url":null,"abstract":"<p><strong>Background: </strong>The biosimilar drug of natalizumab was marketed with a new anti-John Cunningham virus (JCV) assay (Immunowell<sup>TM</sup>).</p><p><strong>Objectives: </strong>To compare the performance of the Immunowell<sup>TM</sup> JCV assay to Stratify<sup>TM</sup>, the reference one.</p><p><strong>Methods: </strong>We analyzed retrospectively serological results from patients with multiple sclerosis (MS) followed in four French MS centers and tested simultaneously in routine with both tests.</p><p><strong>Results: </strong>Two hundred and fifty-nine patients were included. Results were positive in 23.6% with Stratify<sup>TM</sup> and 61.4% with Immunowell<sup>TM</sup>. A binary discordance was found in 37.8%. Sensitivity and negative predictive value were 100%, with lower specificity (50.5%) and positive predictive value (38.4%) for Immunowell<sup>TM</sup>. According to index value cutoffs, 42.9% of the results showed discordances, with a systematic higher risk estimate for Immunowell<sup>TM</sup>. Most of them (83/111) were negative with Stratify<sup>TM</sup> and at low risk of progressive multifocal leukoencephalopathy (PML) (<0.8) with Immunowell<sup>TM</sup>. Eighteen were upgraded to intermediate risk (0.8-1.4) and 10 to high risk (⩾1.4).</p><p><strong>Conclusions: </strong>The Immunowell<sup>TM</sup> JCV IgG assay is reliable to detect patients at risk of progressive multifocal leukoencephalopathy, but the high rate of discrepancy is challenging in deciding to continue on natalizumab or not.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":"31 7","pages":"877-881"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. 生物仿制药natalizumab时代的诊断不确定性——统一抗jcv抗体检测的案例。
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-06-01 Epub Date: 2025-06-14 DOI: 10.1177/13524585251346658
Tjalf Ziemssen, Diego Centonze
{"title":"Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing.","authors":"Tjalf Ziemssen, Diego Centonze","doi":"10.1177/13524585251346658","DOIUrl":"https://doi.org/10.1177/13524585251346658","url":null,"abstract":"","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":"31 7","pages":"751-753"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis. 重复SDMT测试和多发性硬化症的练习效果和噪音的平台。
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-05-31 DOI: 10.1177/13524585251344794
Lenka Novakova, Igal Rosenstein, Markus Axelsson, Menno M Schoonheim, Ralph Hb Benedict, Tom A Fuchs
{"title":"Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis.","authors":"Lenka Novakova, Igal Rosenstein, Markus Axelsson, Menno M Schoonheim, Ralph Hb Benedict, Tom A Fuchs","doi":"10.1177/13524585251344794","DOIUrl":"https://doi.org/10.1177/13524585251344794","url":null,"abstract":"<p><strong>Background: </strong>The Symbol Digit Modalities Test (SDMT) is the most widely used test of cognition in people with multiple sclerosis (PwMS), and repeated testing is confounded by test-retest noise and practice effects.</p><p><strong>Objective: </strong>To investigate the extent to which SDMT practice effects build and plateau with high-frequency testing, reliable cutoffs for longitudinal change, and whether short-interval testing improves detection of cognitive decline.</p><p><strong>Methods: </strong>PwMS were tested with the SDMT monthly across 3 years. Plateau regression analyses were used to determine inflection points of practice effects, and the reliable-change was assessed. To evaluate effects of testing density on cognitive decline detection, this sample was compared with a separate low-density testing group.</p><p><strong>Results: </strong>The study included 71 people with relapsing-remitting MS (77.5% female), mean (standard deviation (SD)) age 37.3 (9.3), with 27.8 (21.3) SDMT assessments over 3.2 (2.4) years. The plateau of practice effects was reached after 18 repetitions (<i>p</i> < 0.001). Within this sample, ⩾7-point SDMT change was needed to detect cognitive decline with 90% confidence. Higher testing density did not improve detection of cognitive decline (<i>p</i> = 0.256).</p><p><strong>Conclusion: </strong>We observed practice effects building for eighteen SDMT assessments and test-retest variability consistent with literature. These results provide guidance on SDMT which should be accounted for with alternate versions and reliable-change methodologies.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"13524585251344794"},"PeriodicalIF":0.0,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144192660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should natalizumab be used despite JC virus positivity? No. 尽管JC病毒呈阳性,那他珠单抗是否仍应使用?否。
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-05-30 DOI: 10.1177/13524585251346382
Gloria Dalla Costa, Melinda Magyari, Per Soelberg Sorensen
{"title":"Should natalizumab be used despite JC virus positivity? No.","authors":"Gloria Dalla Costa, Melinda Magyari, Per Soelberg Sorensen","doi":"10.1177/13524585251346382","DOIUrl":"https://doi.org/10.1177/13524585251346382","url":null,"abstract":"","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"13524585251346382"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should natalizumab be used despite JC virus positivity?-Commentary. 尽管JC病毒呈阳性,仍应使用那他珠单抗吗?
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-05-30 DOI: 10.1177/13524585251346378
Anna Karin Hedström
{"title":"Should natalizumab be used despite JC virus positivity?-Commentary.","authors":"Anna Karin Hedström","doi":"10.1177/13524585251346378","DOIUrl":"10.1177/13524585251346378","url":null,"abstract":"","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"13524585251346378"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder. 多发性硬化症和水通道蛋白-4- igg阳性视神经脊髓炎谱系障碍患者开放压力升高的评估
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-05-26 DOI: 10.1177/13524585251340841
Sydney Roston, Melanie H Quick, Nanthaya Tisavipat, Natthapon Rattanathamsakul, Laura Cacciaguerra, Deena A Tajfirouz, Kevin D Chodnicki, Jan-Mendelt Tillema, Sean J Pittock, Eoin P Flanagan, John J Chen
{"title":"Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.","authors":"Sydney Roston, Melanie H Quick, Nanthaya Tisavipat, Natthapon Rattanathamsakul, Laura Cacciaguerra, Deena A Tajfirouz, Kevin D Chodnicki, Jan-Mendelt Tillema, Sean J Pittock, Eoin P Flanagan, John J Chen","doi":"10.1177/13524585251340841","DOIUrl":"https://doi.org/10.1177/13524585251340841","url":null,"abstract":"<p><p>Increased intracranial pressure (ICP) is increasingly recognized in myelin oligodendrocyte glycoprotein antibody-associated disease but has not been systematically explored in other demyelinating conditions. This cross-sectional study examines the features of raised ICP in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). Lumbar puncture opening pressure (OP) done within 30 days of an attack was identified in 41 NMOSD patients and 37 MS patients. Raised OP was present in 7 (17.1%) NMOSD patients and 4 (10.8%) MS patients who were largely asymptomatic, partially explained by obesity, and did not require ICP lowering medications beyond acute treatment with corticosteroids.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"13524585251340841"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association of HLA-DQB1*04 and DQB1*03 with neuromyelitis optica spectrum disorders: A case-control study considering genetic ancestry. HLA-DQB1*04和DQB1*03与视神经脊髓炎谱系障碍的关系:考虑遗传血统的病例对照研究
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2025-05-26 DOI: 10.1177/13524585251336641
Jaime Toro, Jairo Gaitán, Juliana Lago, Helena Groot, Juan Pablo Noriega, Daniela Sofia Rodriguez-Silva, Carolina Restrepo-Aristizábal, Cesar Franco, Mariana Torres-Bustamante, Angie Montejo, Luisa Márquez, Diana M Narváez, David Felipe Cuellar-Giraldo, Habib Moutran-Barroso, Fabian Cortés-Muñoz, Daniel León, Thomas Felipe Medina, Laura Andrea Serna-Corredor, Saúl Reyes
{"title":"The association of HLA-DQB1*04 and DQB1*03 with neuromyelitis optica spectrum disorders: A case-control study considering genetic ancestry.","authors":"Jaime Toro, Jairo Gaitán, Juliana Lago, Helena Groot, Juan Pablo Noriega, Daniela Sofia Rodriguez-Silva, Carolina Restrepo-Aristizábal, Cesar Franco, Mariana Torres-Bustamante, Angie Montejo, Luisa Márquez, Diana M Narváez, David Felipe Cuellar-Giraldo, Habib Moutran-Barroso, Fabian Cortés-Muñoz, Daniel León, Thomas Felipe Medina, Laura Andrea Serna-Corredor, Saúl Reyes","doi":"10.1177/13524585251336641","DOIUrl":"https://doi.org/10.1177/13524585251336641","url":null,"abstract":"<p><strong>Background: </strong>Internationally, specific human leukocyte antigen (HLA) class II alleles have been associated with neuromyelitis optica spectrum disorder (NMOSD) risk.</p><p><strong>Objective: </strong>To establish the association between HLA class II alleles and NMOSD in a Colombian population, while considering genetic ancestry.</p><p><strong>Methods: </strong>A multicenter case-control study was conducted with NMOSD patients diagnosed with the 2015 Wingerchuk criteria. HLA-DRB1 and HLA-DQB1 alleles were identified using sequence-specific primer polymerase chain reaction (SSP-PCR). Mitochondrial hypervariable region 1 was amplified, and haplogroups were determined with HaploGrep software. Genomic ancestry was assessed with ancestry-informative markers. Associations between HLA polymorphisms and NMOSD were analyzed using logistic regression models.</p><p><strong>Results: </strong>In total, 82 patients with NMOSD (mean age 43.8 ± 13.3 years; 83% females) and 164 controls (mean age 36.4 ± 11.5 years; 85% females) were enrolled. Mitochondrial haplogroup frequencies were similar between groups. Ancestry analysis revealed distinct population structures. In multivariable logistic regression, the HLA-DQB1*04 allele was significantly associated with increased NMOSD risk (odds ratio (OR) = 3.16, confidence interval (CI): 1.58-6.34, <i>p</i> < 0.0023), while the HLA-DQB1*03 allele was associated with a protective effect (OR = 0.23, CI: 0.12-0.46, <i>p</i> < 0.0023).</p><p><strong>Conclusion: </strong>HLA-DQB1*04 allele may increase susceptibility to NMOSD, while DQB1*03 allele could exert a protective effect in our population.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"13524585251336641"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信